Fulvestrant

Generic Name: Fulvestrant

Brand Names: Faslodex, Fulvestrant Mylan

Drug Type: Small Molecule

Chemical Formula: C_₃₂H_₄₇F_₅O_₃S

CAS Number: 129453-61-8

Unique Ingredient Identifier: 22X328QOC4

Background: Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatment of breast cancers, it is also used in combination with alpelisib for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer

Indication: For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.

Associated Conditions: Advanced Breast Cancer, Advanced or Metastatic Breast Cancer

Associated Therapies: -

Clinical Trials

Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor

Phase 3

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Ipatasertib
Drug: Fulvestrant
Other: Placebo

First Posted Date: 2020-12-02

Last Posted Date: 2024-07-31

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 250

Registration Number: NCT04650581

Locations: 🇨🇦
QEII Health Sciences Centre, Halifax, Nova Scotia, Canada
🇨🇦
Centre Integre de Sante et de Services Sociaux, Greenfield Park, Quebec, Canada
🇨🇦
CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada

and more 36 locations

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Locally Advanced or Metastatic Non-small Cell Lung Cancer
Locally Advanced or Metastatic Castration-resistant Prostate Cancer
Locally Advanced or Metastatic ER+ HER2- Breast Cancer

Interventions: Drug: PF-07248144
Drug: Fulvestrant
Drug: Letrozole
Drug: PF-07220060
Drug: Palbociclib

First Posted Date: 2020-10-28

Last Posted Date: 2024-04-03

Lead Sponsor: Pfizer

Target Recruit Count: 186

Registration Number: NCT04606446

Locations: 🇺🇸
Thomas Jefferson University, Gibbon Building, Philadelphia, Pennsylvania, United States
🇺🇸
Thomas Jefferson University, Investigational Drug Service, Philadelphia, Pennsylvania, United States
🇺🇸
Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization, Philadelphia, Pennsylvania, United States

and more 51 locations

ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL

Phase 2

Active, not recruiting

Conditions: Breast Cancer Metastatic

Interventions: Drug: Paclitaxel
Drug: Abemaciclib
Drug: Letrozole
Drug: Fulvestrant

First Posted Date: 2020-10-26

Last Posted Date: 2024-07-05

Lead Sponsor: MedSIR

Target Recruit Count: 162

Registration Number: NCT04603183

Locations: 🇪🇸
Hospital Clinico Universitario de Valencia, Valencia, Spain
🇮🇹
Instituto Europeo di Oncologia, Milano, Italy
🇮🇹
Azienda Ospedaliero-Universitaria Cittá de la Salute e della Scienza, Torino, Italy

and more 28 locations

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Phase 2

Active, not recruiting

Conditions: Biliary Tract Neoplasms
Uterine Neoplasms
Urologic Neoplasms
Carcinoma, Non-Small-Cell Lung
HER2 Mutations Breast Neoplasms
Uterine Cervical Neoplasms

Interventions: Drug: tucatinib
Drug: trastuzumab
Drug: fulvestrant

First Posted Date: 2020-10-08

Last Posted Date: 2024-11-13

Lead Sponsor: Seagen Inc.

Target Recruit Count: 217

Registration Number: NCT04579380

Locations: 🇺🇸
HealthPartners Institute, Saint Louis Park, Minnesota, United States
🇺🇸
Texas Oncology, P.A. - Dallas, Dallas, Texas, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 63 locations

A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer

Phase 1

Active, not recruiting

Conditions: Breast Neoplasms

Interventions: Drug: E7090
Drug: Fulvestrant
Drug: Exemestane

First Posted Date: 2020-10-01

Last Posted Date: 2024-12-03

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 72

Registration Number: NCT04572295

Locations: 🇯🇵
Eisai Trial Site 10, Kitaadachi-gun, Saitama, Japan
🇯🇵
Eisai Trial Site 2, Shinagawa-ku, Tokyo, Japan
🇯🇵
Eisai Trial Site 6, Kashiwa, Chiba, Japan

and more 8 locations

DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Adjuvant Therapy
Drug: Palbociclib
Drug: Fulvestrant

First Posted Date: 2020-09-28

Last Posted Date: 2023-03-21

Lead Sponsor: Criterium, Inc.

Target Recruit Count: 100

Registration Number: NCT04567420

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
University of Wisconsin Clinical Science Center, Madison, Wisconsin, United States

and more 12 locations